The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
The Chemours CompanyNYSE: CC
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $80M fell 13.0% year over year, ahead of the -29.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, up 0.6 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -13.0% holds above the trailing-twelve-month pace of -29.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 340M USD
- Year-over-year change
- +13.0%
- 4-year CAGR
- +1.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 340M | +13.0% |
| FY2024 | 2024-12-31 | 301M | -2.0% |
| FY2023 | 2023-12-31 | 307M | +5.5% |
| FY2022 | 2022-12-31 | 291M | -8.2% |
| FY2021 | 2021-12-31 | 317M | — |
Depreciation & Amortization vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 depreciation & amortization of $238M is the 7th highest of the 19 companies compared; the peer median is $174.75M.
- Its year-over-year change of -29.2% is the 17th highest of 19, against a peer median of +3.1%.
- Depreciation & amortization amounts to 4.1% of revenue for CC, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.83B | +2.7% | -3.6% | 10.8% | |
| LTM Sep 2026 | $1.44B | +3.6% | +3.1% | 4.5% | |
| LTM Sep 2026 | $1.16B | -0.4% | +3.7% | 10.1% | |
| LTM Jun 2026 | $948M | -2.2% | -6.6% | 9.5% | |
| LTM Jun 2026 | $538M | +8.9% | +1.7% | 3.3% | |
| LTM Jun 2026 | $303M | +5.2% | -0.9% | 5.9% | |
| LTM Jun 2026 | $238M | -29.2% | +5.3% | 4.1% | |
| LTM Sep 2026 | $196.64M | +18.2% | +16.2% | 12.9% | |
| LTM Jun 2026 | $191M | -33.2% | -0.6% | 10.4% | |
| LTM Jun 2026 | $180M | +19.2% | +1.8% | 5.0% | |
| LTM Sep 2026 | $169.5M | +11.7% | -2.1% | 4.9% | |
| LTM Aug 2026 | $138.46M | -22.6% | +6.7% | 3.9% | |
| LTM Mar 2026 | $133.1M | +4.1% | +7.7% | 7.4% | |
| LTM Jun 2026 | $80.68M | +19.1% | +4.0% | 10.7% | |
| LTM Sep 2026 | $75.99M | -15.0% | +5.1% | 3.8% | |
| LTM Mar 2026 | $75.96M | -11.4% | -0.2% | 9.3% | |
| LTM Jun 2026 | $62.19M | +2.1% | +5.2% | 3.7% | |
| LTM Mar 2026 | $9.89M | +10.8% | -2.6% | 9.0% | |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding CC) | $174.75M | +3.1% | +1.8% | 6.7% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.